This is the authors' abstract. We don't add key points for this paper.
These observations suggest the importance of ADCC activity as an immunologic mechanism of cetuximab in biological therapy for lung cancer patients.
No takes yet. Share an insight, caveat, or question.
Kurai et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: